← Leaderboards
Joseph Robert Testa
Fox Chase Cancer Center
$17,947,194
Attributed
$22,331,461
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–24$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,331,461 · 11
By mechanism
R01$15,285,517 · 5
P50$2,291,841 · 1
P01$1,875,535 · 1
P42$1,363,128 · 1
P30$1,327,440 · 2
R03$188,000 · 1
Top collaborators
- Jonathan D. Chernoff10 shared
- Siddharth Balachandran5 shared
- Frank J. Rauscher5 shared
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorGeneticIn VivoMouse ModelPathogenesisAsbestosCellsResistanceMalignant MesotheliomaTumorigenesisPathway InteractionsBiologicalTumor Suppressor ProteinsGene ExpressionMolecularExposure ToBaseTumor Suppressor GenesSignal TransductionMesothelial CellPlayIncidenceOncogenes
Grant awards (72)
Role of the Parkinson's susceptibility gene LRRK2 in NFAT-mediated malignant mesothelioma tumorigenesis$94,000
R03 · FY2024 · CA · contact PI
Role of the Parkinson's susceptibility gene LRRK2 in NFAT-mediated malignant mesothelioma tumorigenesis$94,000
R03 · FY2023 · CA · contact PI
Shared Resource: Genomics Facility$30,266
P30 · FY2021 · CA · contact PI
Role of STE20 protein kinases in malignant mesothelioma$444,125
R01 · FY2020 · CA
Shared Resource: Genomics Facility$192,011
P30 · FY2020 · CA · contact PI
Shared Resource: Genomics Facility$8,696
P30 · FY2020 · CA · contact PI
Role of STE20 protein kinases in malignant mesothelioma$421,586
R01 · FY2019 · CA
RIP1/3 Kinases as New Targets in Malignant Mesothelioma$410,657
R01 · FY2019 · CA · contact PI
Shared Resource: Genomics Facility$179,643
P30 · FY2019 · CA · contact PI
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXL$529,284
R01 · FY2018 · CA · contact PI
Role of STE20 protein kinases in malignant mesothelioma$434,625
R01 · FY2018 · CA
RIP1/3 Kinases as New Targets in Malignant Mesothelioma$423,359
R01 · FY2018 · CA · contact PI
Shared Resource: Genomics Facility$171,630
P30 · FY2018 · CA · contact PI
Shared Resource: Genomics Facility$10,870
P30 · FY2018 · CA · contact PI
Shared Resource: Genomics Facility$5,968
P30 · FY2018 · CA · contact PI
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXL$556,046
R01 · FY2017 · CA · contact PI
RIP1/3 Kinases as New Targets in Malignant Mesothelioma$435,685
R01 · FY2017 · CA · contact PI
Role of STE20 protein kinases in malignant mesothelioma$434,625
R01 · FY2017 · CA
Biomedical Project 4 - Animal Models of Mesothelioma$328,008
P42 · FY2017 · ES · contact PI
Shared Resource: Genomics Facility$171,623
P30 · FY2017 · CA · contact PI
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXL$543,681
R01 · FY2016 · CA · contact PI
RIP1/3 Kinases as New Targets in Malignant Mesothelioma$426,992
R01 · FY2016 · CA · contact PI
Role of STE20 protein kinases in malignant mesothelioma$423,938
R01 · FY2016 · CA
Biomedical Project 4 - Animal Models of Mesothelioma$353,168
P42 · FY2016 · ES · contact PI
Shared Resource: Genomics Facility$164,297
P30 · FY2016 · CA · contact PI
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXL$527,579
R01 · FY2015 · CA · contact PI
RIP1/3 Kinases as New Targets in Malignant Mesothelioma$414,666
R01 · FY2015 · CA · contact PI
The Role of p21-Activated Kinases in Malignant Mesothelioma$370,388
R01 · FY2015 · CA
Biomedical Project 4 - Animal Models of Mesothelioma$334,479
P42 · FY2015 · ES · contact PI
Pathogenesis of Malignant Mesothelioma by the Human Polycomb Complex BAP1-ASXL$527,579
R01 · FY2014 · CA · contact PI
The Role of p21-Activated Kinases in Malignant Mesothelioma$359,276
R01 · FY2014 · CA
Biomedical Project 4 - Animal Models of Mesothelioma$347,473
P42 · FY2014 · ES · contact PI
Basis for Lymphomagenesis in Akt2 Transgenic Mice$374,544
R01 · FY2013 · CA · contact PI
The Role of p21-Activated Kinases in Malignant Mesothelioma$348,165
R01 · FY2013 · CA
Basis for Lymphomagenesis in Akt2 Transgenic Mice$410,451
R01 · FY2012 · CA · contact PI
The Role of p21-Activated Kinases in Malignant Mesothelioma$369,695
R01 · FY2012 · CA
Basis for Lymphomagenesis in Akt2 Transgenic Mice$419,987
R01 · FY2011 · CA · contact PI
The Role of p21-Activated Kinases in Malignant Mesothelioma$366,583
R01 · FY2011 · CA
Basis for Lymphomagenesis in Akt2 Transgenic Mice$452,084
R01 · FY2010 · CA · contact PI
AKT AND TUMOR SUPPRESSOR PATHWAYS IN MESOTHELIOMA$385,739
P01 · FY2010 · CA · contact PI
Basis for Lymphomagenesis in Akt2 Transgenic Mice$418,237
R01 · FY2009 · CA · contact PI
AKT AND TUMOR SUPPRESSOR PATHWAYS IN MESOTHELIOMA$379,860
P01 · FY2009 · CA · contact PI
AKT as a Biomarker of Ovarian Cancer Progression and a Target for Therapy$799,787
P50 · FY2008 · CA · contact PI
AKT AND TUMOR SUPPRESSOR PATHWAYS IN MESOTHELIOMA$362,882
P01 · FY2008 · CA · contact PI
AKT as a Biomarker of Ovarian Cancer Progression and a Target for Therapy$732,444
P50 · FY2007 · CA · contact PI
AKT AND TUMOR SUPPRESSOR PATHWAYS IN MESOTHELIOMA$353,790
P01 · FY2007 · CA · contact PI
AKT AND TUMOR SUPPRESSOR PATHWAYS IN MESOTHELIOMA$393,264
P01 · FY2006 · CA · contact PI
AKT2 Function and Oncogenic Activity$392,240
R01 · FY2006 · CA · contact PI
Molecular Genetic Alterations in Malignant Mesothelioma$369,746
R01 · FY2006 · CA · contact PI
AKT as a Biomarker of Ovarian Cancer Progression and a Target for Therapeutic Int$103,697
P50 · FY2006 · CA · contact PI
AKT2 Function and Oncogenic Activity$420,343
R01 · FY2005 · CA
Molecular Genetic Alterations in Malignant Mesothelioma$367,618
R01 · FY2005 · CA
AKT as a Biomarker of Ovarian Cancer Progression and a Target for Therapeutic Int$110,503
P50 · FY2005 · CA
AKT2 Function and Oncogenic Activity$462,064
R01 · FY2004 · CA
Molecular Genetic Alterations in Malignant Mesothelioma$356,908
R01 · FY2004 · CA
AKT as a Biomarker of Ovarian Cancer Progression and a Target for Therapeutic Int$103,752
P50 · FY2004 · CA
AKT2 Function and Oncogenic Activity$396,934
R01 · FY2003 · CA
Molecular Genetic Alterations in Malignant Mesothelioma$346,513
R01 · FY2003 · CA
AKT2 Function and Oncogenic Activity$382,920
R01 · FY2002 · CA
Molecular Genetic Alterations in Malignant Mesothelioma$338,422
R01 · FY2002 · CA
CORE--RESEARCH CYTOGENETICS$196,218
P30 · FY2002 · CA
Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis$165,355
P50 · FY2002 · CA
AKT2 FUNCTION AND ONCOGENIC ACTIVITY$310,502
R01 · FY2001 · CA
CORE--RESEARCH CYTOGENETICS$196,218
P30 · FY2001 · CA
Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis$165,355
P50 · FY2001 · CA
CORE--RESEARCH CYTOGENETICS$0
P30 · FY2001 · CA
CORE--RESEARCH CYTOGENETICS$0
P30 · FY2001 · CA
AKT2 FUNCTION AND ONCOGENIC ACTIVITY$297,470
R01 · FY2000 · CA
Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis$55,474
P50 · FY2000 · CA
Role of PI3 kinase/AKT2 signaling in ovarian oncogenesis$55,474
P50 · FY2000 · CA
CORE--RESEARCH CYTOGENETICS$0
P30 · FY2000 · CA
CORE--RESEARCH CYTOGENETICS$0
P30 · FY2000 · CA